Results 41 to 50 of about 155 (115)

Ketamine Dosing Across Clinical Indications: A Narrative Review Organized by Proposed NMDA‐Related Mechanisms

The Journal of Clinical Pharmacology, Volume 66, Issue 6, June 2026.
Abstract Ketamine is a non‐competitive antagonist at the N‐methyl‐D‐aspartate (NMDA) glutamate receptor. It was approved by the US Food and Drug Administration for anesthesia in 1970. The only other related US regulatory approval since then has been for esketamine nasal spray for depression in 2019. Over this time ketamine has been repurposed by mainly
Paul Glue, Ben Beaglehole
wiley   +1 more source

Esketamine/Ketamine: Dual‐Action Mechanisms and Clinical Prospects beyond Anesthesia in Psychiatry, Immunology, and Oncology

Advanced Science, Volume 13, Issue 7, 3 February 2026.
Esketamine and ketamine are widely used for perioperative analgesia and anesthesia. Despite their established roles in analgesia, sedation, and anesthesia, as well as emerging antidepressant, anti‐tumor, and anti‐inflammatory effects, their clinical use is limited due to side effects and addiction potential.
Yinxin Wang, Jiangang Xu, Xinyu Zhou, Lu Che, Minghan Qiu, Yang Liu, Ming Gao, Zhen Yang   +7 more
wiley   +1 more source

Trauma re-experiencing episodes during esketamine treatment in patients with treatment-resistant depression and comorbid PTSD: a retrospective case series

European Journal of Psychotraumatology
Background: Posttraumatic stress disorder (PTSD) is a severe and frequent affection that is highly comorbid to major depressive disorder. Comorbid PTSD and depression increase the risk of treatment-resistant depression (TRD), with a high risk of ...
Maud Rothärmel, Lila Mekaoui, François Kazour, Morgane Herrero, Eva-Maria Beetz-Lobono, Aiste Lengvenyte, Jérôme Holtzmann, Philippe Raynaud, Macarena Cuenca, Samuel Bulteau, Pierre De Maricourt, Thomas Husson, Emilie Olié, Bénédicte Gohier, Anne Sauvaget, Raphaël Gaillard, Raphaëlle Richieri, David Szekely, Ludovic Samalin, Olivier Guillin, Virginie Moulier, Wissam El-Hage, Andrew Laurin, Lucie Berkovitch   +23 more
doaj   +1 more source

Ketamine Combined With Psychotherapy as a Treatment for Resistant Depression in a Public European Hospital

Brain and Behavior, Volume 16, Issue 1, January 2026.
This retrospective study evaluated ketamine infusions combined with psychotherapy in nine patients with treatment‐resistant depression at a general hospital. After eight weeks, all participants improved, with PHQ‐9 scores shifting from severe to moderate. Overall, 44% responded to treatment, and among those with suicidal ideation, more than half showed
Filipa Alves da Silva, Rita Avelar, Bernardo Peixoto, Leonor Bacelar‐Nicolau, Francisco Santos, João Costa Ribeiro, Maria João Heitor   +6 more
wiley   +1 more source

A Novel Tertiary Carbamate Prodrug Strategy to Overcome Metabolic Barriers in Oral Ketamine Delivery

ChemMedChem, Volume 21, Issue 2, January 2026.
This study describes the development of an orally optimized ketamine prodrug designed to improve pharmacokinetic properties, extend therapeutic efficacy, and minimize adverse effects and abuse liability. Ketamine, a rapid‐acting N‐methyl‐D‐aspartate (NMDA) receptor antagonist, has therapeutic potential beyond anesthesia, including treatment‐resistant ...
Juulia Järvinen, Santosh Kumar Adla, Janne Tampio, Aaro Jalkanen, Kenneth B. Sloan, Kristiina M. Huttunen, Jarkko Rautio   +6 more
wiley   +1 more source

A Review of Nanoparticle‐Based Astrocyte Modulation in CNS Disorders: Evaluating the Underexplored Potential of Intranasal Delivery

Nano Select, Volume 7, Issue 1, January 2026.
Nanoparticle‐driven nose‐to‐brain drug delivery offers a noninvasive approach to bypass the blood–brain barrier (BBB) and directly modulate reactive astrocytes in CNS disorders. This review highlights biodegradable nanoparticles for astrocyte modulation, enhancing drug bioavailability, sustained release, and neuroinflammation control.
Senamile M. Dlamini, Gillian D. Mahumane, Pradeep Kumar, Yahya E. Choonara   +3 more
wiley   +1 more source

Intranasal esketamine for ECT-refractory bipolar depression: a case report

Frontiers in Psychiatry
This is a case report of a 52 year old female with ECT-refractory bipolar depression who was treated with esketamine nasal spray, leading to a noticeable improvement in her depressive symptoms.
Muhammad Abbas, Bruno Kallas, Max Garris
doaj   +1 more source

The Ketamine Trial for Acute Suicidality (KETA): Study Protocol of a Double‐Blind Randomized Placebo‐Controlled Superiority Trial on Intranasal Racemic Ketamine Compared to the Active Placebo Intranasal Midazolam as Treatment for Acute Suicidality

International Journal of Methods in Psychiatric Research, Volume 34, Issue 4, December 2025.
ABSTRACT Background Suicidality is a transdiagnostic entity in patients with and without psychiatric disorders. Ketamine is a novel treatment for treatment‐resistant depression with favorable effects on related suicidality in this population. Little is known about the effects of ketamine on suicidality as a distinct phenomenon.
Jurriaan F. M. Strous, Gijs H. J. Roelandt, Jens H. van Dalfsen, Jeanine Kamphuis, Radboud M. Marijnissen, Robert A. Schoevers   +5 more
wiley   +1 more source

Effectiveness and Tolerability of Intranasal Esketamine in Treatment-Resistant Depression: Report of Two Clinical Cases

European Psychiatry, 2023
Introduction Major depressive disorder (MDD) is a mental health disorder characterised by persistently low mood; anhedonia; feelings of worthlessness and guilt; altered appetite, weight and sleep and suicidal ideation. About one-third of patients do not
A. Mercado-Rodríguez, C. Martín Requena, A. Cano Baena, I. Zorrilla Martínez, A. González-Pinto Arrillaga, L. Mar-Barrutia   +5 more
doaj   +1 more source

Development and Validation of a Rapid LC–MS/MS Method for Plasma Analysis of Ketamine, Norketamine, Dehydronorketamine, and Hydroxynorketamine

Biomedical Chromatography, Volume 39, Issue 9, September 2025.
ABSTRACT Ketamine, a well‐established dissociative anesthetic, has recently gained significant attention for its rapid‐acting antidepressant effects, particularly in treatment‐resistant depression. In this study, we developed and validated a state‐of‐the‐art liquid chromatography–tandem mass spectrometry (LC–MS/MS) method for the bioanalysis of ...
Jan Thomann, Selina Kraus, Livio Erne, Severin B. Vogt, Matthias E. Liechti, Dino Luethi   +5 more
wiley   +1 more source